Adverse drug reactions associated with the administration of amphotericin B lipid complex (Abelcet)
1
We have recently reported our experience with Abelcet in the British Journal of Haematology.
2 Thirty-two evaluable patients were treated with Abelcet at a median dose of 4.8 mg/kg/day for suspected or proven fungal infection in patients treated for haematological malignancy. The duration of treatment was a median of 14 days (range 4-42) and the efficacy was good with 78% of patients responding to treatment. Amongst the 32 patients, five of eight patients with proven fungal infection responded to Abelcet. Toxicity in this study was limited and in particular renal function tended to improve on treatment from median serum creatinine levels of 173 mol/l (range 65-310) to a median serum creatinine level of 145 mol/l (range 63-340). Hypokalaemia (50% fell to Ͻ3 mmol/l) and hypomagnesaemia (78%, Ͻ0.7 mmol/l) were seen no more frequently than with AmBisome. The incidence of fevers and chills was greater with Abelcet than with liposomal amphotericin B, although this did not require a change in anti-fungal therapy.
We are currently evaluating the efficacy of low-dose ABLC (LD ABLC, 2 mg/kg/day) in neutropenic patients being treated with chemotherapy for haematological malignancy, including blood and bone marrow stem cell transplantation who are experiencing toxicity (pre-existing renal disease, serum creatinine Ͼ170 mol/l whilst receiving amphotericin B or development of other amphotericin Brelated toxicity) or failing to respond to ConAmB. Patients considered at high risk of invasive fungal infection or with documented fungal infection are excluded from this study. To date, 12 patients have been treated (allo-BMT n = 4, auto-BMT n = 4, chemotherapy n = 4) with a median age of 39 years (range 18-66). Patients received a mean dose of 2.32 ± 0.13 (±s.e.m.) mg/kg/day for a median of 5 days (range 1-12). Eight of 12 patients responded to LD ABLC (resolution of fever for Ͼ3 days) with a median time to response of 4 days (range 3-5) and no patient died whilst on study. All patients received additional potentially nephrotoxic drugs and three patients commenced LD ABLC with abnormal serum creatinine levels and demonstrated a mean improvement of 16.6 ± 6.64%. Otherwise, no significant change in serum creatinine was detected in the remaining patients (P = 0.86). Toxicity was limited: nine reports of toxicity directly attributable to ABLC were reported after 63 administrations (12.3%; fever n = 2, rigors n = 4, GI n = 1, abnormal LFTs n = 2). No patient demonstrated signs or symptoms of anaphylaxis.
We have consulted the Medicines Control Agency which monitors drug adverse events in the UK by spontaneous reporting of adverse events on the Adverse Drug On-line Information tracking (ADROIT) system. They have had no reports regarding defects in the preparation and manufacturing of Abelcet suggesting that batch variability is an unlikely cause of the clinical problems reported by Ringden. With regard to adverse events, a total of 12 reports have been received since 9 May 1995, which describes 21 reactions (personal communication). These adverse events included tachycardia (n = 1), hypokalaemia and hypomagnesaemia (n = 2), general reactions including rigors (n = 7) and renal impairment (n = 3). No fatalities have been reported. Although this reporting process is not systematic this seems a low level of reactions. The incidence of reported adverse drug reactions with one of the other lipid-based amphotericin B products, Ambisome, was similar to that reported for Abelcet (personal communication). Since 24 January 1992, there have been a total of 34 reports disclosing a total of 70 reactions, again no fatalities have been documented. Whilst it is difficult to make direct numerical comparisons between products using ADROIT data unless they take account of variations in the level of reporting, the extent of use and the promotion and publicity of the products, 3 these figures correlate with those reported in randomised trials 4 and suggest that the toxicity associated with these lipid amphotericin formulations are broadly similar and are considerably less than those experienced by Ringden et al. Therefore, in conclusion, we have extensive clinical experience in adults with lipid formulations of amphotericin B, particularly Abelcet, and have not noted the degree of adverse reactions reported by Ringden et al. Our experience is in keeping with the national reporting rates of adverse drug reactions with both these products to the Medicines Control Agency (UK). We find it difficult to reconcile our own experience with the conclusion of Ringden et al. 
